TriangleNCT00954174 · OUTCOME
Patient Reported Peripheral Neuropathy Symptoms - Baseline
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- units on a scale-baseline
- Interval / dispersion
- Standard Error
- Time frame
- Baseline (Pre cycle 1)
What was measured
Patient reported peripheral neuropathy symptoms was measured with the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - neurotoxicity subscale (short version) (FACT/GOG-Ntx subscale). The FACT/GOG-Ntx subscale contains 11 items. Each item was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). . The Ntx score ranges 0-44 with a large score suggesting less peripheral neuropathy symptoms. Quality of Life was analyzed across cohorts since disease site was considered independent of Quality of Life.
Analysis population: Subjects who provided baseline assessment
Groups in this outcome
Regimen I - Uterine and Non-Uterine Subjects
Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30-60 minutes on day 1. Carboplatin: Given IV Paclitaxel: Given IV Quality-of-Life Assessment: Ancillary studies
Regimen II - Uterine and Non-Uterine Subjects
Patients receive ifosfamide IV over 1 hour on days 1-3 followed by paclitaxel as in Arm I. Ifosfamide: Given IV Paclitaxel: Given IV Quality-of-Life Assessment: Ancillary studies
| Group | Source count |
|---|---|
| Regimen I - Uterine and Non-Uterine Subjects | 205 |
| Regimen II - Uterine and Non-Uterine Subjects | 184 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Regimen I - Uterine and Non-Uterine Subjects | 40.2 | 0.3 | Not reported | Not reported | Not reported |
| Regimen II - Uterine and Non-Uterine Subjects | 41.0 | 0.3 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 0.3
- value
- 40.2
- group Id
- OG001
- spread
- 0.3
- value
- 41.0
- denoms
- counts
- group Id
- OG000
- value
- 205
- group Id
- OG001
- value
- 184
- units
- Participants
- description
- Patient reported peripheral neuropathy symptoms was measured with the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - neurotoxicity subscale (short version) (FACT/GOG-Ntx subscale). The FACT/GOG-Ntx subscale contains 11 items. Each item was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). . The Ntx score ranges 0-44 with a large score suggesting less peripheral neuropathy symptoms. Quality of Life was analyzed across cohorts since disease site was considered independent of Quality of Life.
- dispersion Type
- Standard Error
- groups
- description
- Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30-60 minutes on day 1. Carboplatin: Given IV Paclitaxel: Given IV Quality-of-Life Assessment: Ancillary studies
- id
- OG000
- title
- Regimen I - Uterine and Non-Uterine Subjects
- description
- Patients receive ifosfamide IV over 1 hour on days 1-3 followed by paclitaxel as in Arm I. Ifosfamide: Given IV Paclitaxel: Given IV Quality-of-Life Assessment: Ancillary studies
- id
- OG001
- title
- Regimen II - Uterine and Non-Uterine Subjects
- param Type
- MEAN
- population Description
- Subjects who provided baseline assessment
- reporting Status
- POSTED
- time Frame
- Baseline (Pre cycle 1)
- title
- Patient Reported Peripheral Neuropathy Symptoms - Baseline
- type
- SECONDARY
- unit Of Measure
- units on a scale-baseline
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice